Cited by

• Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19.

  Sophonsri A, Le D, Lou M, Ny P, Minejima E, Chambliss AB, Nieberg P, Shriner K, Wong-Beringer A. Sophonsri A, et al. Crit Care Explor. 2022 Sep 7;4(9):e0760. doi: 10.1097/CCE.0000000000000760. eCollection 2022 Sep. Crit Care Explor. 2022. PMID: 38371947 Free PMC article.
• Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients.

  Akama-Garren EH, Li JX. Akama-Garren EH, et al. J Med Virol. 2021 Oct;93(10):5768-5776. doi: 10.1002/jmv.27105. Epub 2021 Jun 2. J Med Virol. 2021. PMID: 34042195 Free PMC article.
• What is the aetiology of dysnatraemia in COVID-19 and how is this related to outcomes in patients admitted during earlier and later COVID-19 waves? A multicentre, retrospective observational study in 11 Dutch hospitals.

  de Haan L, Ten Wolde M, Beudel M, Olde Engberink RHG, Appelman B, Haspels-Hogervorst EK, Rusch D, Gritters van den Oever NC, Simsek S, Paternotte N, van den Bergh JP, Wyers CE, de Kruif MD, Dormans T, Moeniralam H, Bokhizzou N, Brinkman K, Douma R; Dutch COVID-PREDICT study group. de Haan L, et al. BMJ Open. 2023 Nov 14;13(11):e075232. doi: 10.1136/bmjopen-2023-075232. BMJ Open. 2023. PMID: 37963704 Free PMC article.
• Scientific evidence in the COVID-19 treatment: A comprehensive review.

  Iturricastillo G, Ávalos Pérez-Urría E, Couñago F, Landete P. Iturricastillo G, et al. World J Virol. 2021 Sep 25;10(5):217-228. doi: 10.5501/wjv.v10.i5.217. World J Virol. 2021. PMID: 34631473 Free PMC article. Review.
• Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.

  Ghaempanah F, Nikouei M, Cheraghi M, Jahangiri A, Moradi Y. Ghaempanah F, et al. J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w. J Pharm Policy Pract. 2023. PMID: 37986199 Free PMC article.